COVID-19 and Hereditary Metabolic Diseases (COVID19-MHM)

University Hospital, Lille

Status: Unknown

Conditions: Metabolism, Inborn Errors; Covid19

Study type: Observational

Funder types: Other

Identifiers

NCT04645498

2020-A02886-33 (Other Identifier)

2020_52

Details and patient eligibility

About

No additional risk factors have been identified in patients with Inherited Metabolic Diseases (IMD) for contracting or presenting complications of COVID-19 compared to the general population. Yet, IMD patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. We do not know the impact of this infection on patients suffering from MHM, nor the possible effect of specific treatment of MHM on the evolution of COVID-19.

This study will collect French IMD patients having or having had COVID-19 infection. The main objective is to estimate among IMD patients contracting COVID-19 the frequency of disease aggravation or metabolic decompensation.

The secondary objectives will be : a. to evaluate the incidence of COVID-19 diagnosed in a given group of IMD when the number of patients with this IMD is known (Urea Cycle Deficiency, Gaucher Disease). b. to evaluate the impact of IMD on the and severity of COVID-19 infection

Enrollment: 77 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Child or adult patient with a diagnosis of IMD
• Symptomatic or asymptomatic patient tested positive for COVID-19 (PCR and/or serology)
• Symptomatic patient non tested but with strong clinical suspicion for COVID-19
• Patient affiliated with the health insurance

Exclusion criteria

• inability to receive informed information
• Persons deprived of liberty

Trial design

77 participants in 1 patient group

Metabolism, Inborn Errors

Description:

Patient affected by an inherited metabolic disease